IL-10 Antibody (67232) [Unconjugated]

Western blot shows 25 ng of Recombinant Rat IL-10 (Catalog # 522-RLB), Recombinant Human IL-10 (Catalog # 217-IL) and Recombinant Mouse IL-10 (Catalog # 417-ML). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Rat IL-10 Monoclonal Antibody (Catalog # MAB519) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IL-10 at approximately 15 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Nrg-1 promotes Treg cell response in the injured spinal cord. a, b Representative images of the gating strategy for flow cytometry after singlet selection are provided for vehicle- and Nrg-1-treated groups. c At 3-day post-injury, the number of CD3+CD4+ T cells in the spinal cord was significantly higher in vehicle-treated animals compared to uninjured control group. There was no significant difference in the population of infiltrated helper T cells and the number of FoxP3+ Treg cells (CD3+CD4+FoxP3+) between vehicle- and Nrg-1-treated groups. However, the population of IL-10 producing CD4+ T cells (CD3+CD4+IL-10+) was significantly increased in Nrg-1-treated animals in comparison to vehicle-treated group. d At 7 days post-SCI, despite no significant difference in the total helper and regulatory T cell populations between vehicle- and Nrg-1-treated groups, a significant reduction (1.9-fold) was observed in IFN gamma producing effector T cell population in Nrg-1-treated SCI rats compared to their vehicle-treated counterparts. e At 14 days post-SCI, infiltrated helper T cells reached their lowest level among all examined time-points, and Nrg-1 treatment had no significant effect on the total helper T cell population. IL-10 expressing Treg cells were significantly higher in both vehicle and Nrg-1 injured rats compared to uninjured animals. Nrg-1-treated animals showed a significantly higher number of Treg cells in their spinal cord at 14-day time-point compared to vehicle-treated rats. f However, at chronic (42-day) time-point, the number of T helper cells reached a maximum, with Nrg-1-treated animals harboring a significantly decreased population of CD4+ T-cells in their spinal cord compared to the vehicle-treated group. Most importantly, CD3+CD4+FoxP3+ and CD3+CD4+IL-10+ regulatory T cell populations were significantly increased in Nrg-1-treated groups. g Immunohistochemical images show the presence of Treg cells in the perilesional area (N = 5/group/time-point, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA followed by Holm-Sidak post hoc test) Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1093-9), licensed under a CC-BY license. Not internally tested by R&D Systems.

Nrg-1 treatment promotes Breg cell population following SCI. a Representative images of the gating strategy for flow cytometry of spinal cord are provided. b At 7 days post-injury, the number of CD45RA+ B cells was significantly increased in the spinal cord without any significant difference in the total and regulatory B cell populations between vehicle- and Nrg-1-treated groups. c At 14-day post-SCI, a significant increase in the number of Breg cells was observed in Nrg-1-treated animals compared to vehicle-treated group. d Chronically at 42 days post-SCI, the number of B cells in the spinal cord reached the highest level compared to all earlier time-points. Nrg-1 treatment resulted in a significant increase in the number of infiltrated B cells in the spinal cord and promoted IL-10 expressing Breg cells compared to vehicle treatment. e Immunohistochemical analysis verified the presence of Breg cells in the perilesional area of the injured spinal cord. f Representative images of the gating strategy for flow cytometry of blood are provided. g Analysis of the blood revealed a significant decline in B cell population at 7 days post-SCI without any significant change in the Breg cell population at this time-point. h, i No significant change in total and regulatory B cell populations were observed in the blood at 14- and 42-day time-points. (N = 5/group/time-point, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA followed by Holm-Sidak post hoc test) Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1093-9), licensed under a CC-BY license. Not internally tested by R&D Systems.

Comparison between P1 and P12 immunostaining intensities of IL-6 and IL-10 in brain. IL-6 and IL-10 expressions were increased only at P12 in brains of rat pups exposed to HI+/- LPS. Data are presented (A, C) as fold increase of IL-6 and IL-10 expressions compared to control (set at 1). (B) Increased IL-6 staining (arrowheads) in P12 spongiotic frontal cortex (pyknotic neurons with abnormal reduced contrast between nucleus and cytoplasm), and spongiotic underlying external capsule following LPS+HI exposure compared to control. (D) Increased IL-10 staining (arrowheads) in P12 lesioned frontal cortex and underlying external capsule exposed to LPS+HI compared to control. IHC was performed at 48 h post-HI, in 3 to 4 brains under each experimental condition. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA with Newman-Keuls post test. Scale bars = 15 μm (B, D) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/21599903), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Rt
• Applications: WB, ELISA(Cap)
• Clone: 67232
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IL-10 Antibody (67232) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant rat IL‑10
  Ser19-Asn178
  Accession # P29456
• Specificity: Detects rat IL-10 in ELISAs and Western blots. In Western blots, shows approximately 15% cross-reactivity with recombinant mouse IL‑10 and less than 2% cross-reactivity with recombinant human IL-10.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL10
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Rat IL-10 Biotinylated Antibody (Catalog number BAF519)
  Standard: Recombinant Rat IL-10 (Catalog number 522-RL)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-10 Antibody (67232) [Unconjugated]

• CSIF
• CSIFMGC126450
• Cytokine synthesis inhibitory factor
• GVHDS
• IL10
• IL-10
• IL10A
• IL-10MGC126451
• interleukin 10
• interleukin-10
• TGIF

Background

Interleukin 10 (IL-10) is a pleiotropic cytokine that can exert either immunostimulatory or immunosuppressive effects on a variety of cell types. It is produced predominantly by Th2 lymphocytes and other activated lymphoid cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-10 Antibody (MAB519)(6)

Publications using MAB519

• S Dyck, H Kataria, A Alizadeh, KT Santhosh, B Lang, J Silver, S Karimi-Abd Perturbing chondroitin sulfate proteoglycan signaling through LAR and PTP? receptors promotes a beneficial inflammatory response following spinal cord injury J Neuroinflammation, 2018-03-20;15(1):90. 3/20/2018 [PMID: 29558941]
• Samuel Rodrigues Lourenço Morais Strength training prior to muscle injury potentiates low-level laser therapy (LLLT)-induced muscle regeneration Lasers Med Sci, 2016-12-01;0(0):. 12/1/2016 [PMID: 27909917]
• Marie-Elsa Brochu, Sylvie Girard, Karine Lavoie, Guillaume Sébire Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study Journal of Neuroinflammation 12/1/2011 [PMID: 21599903]
• Lee HI, Kim MK, Oh JY, Ko JH, Lee HJ, Wee WR, Lee JH The role of cyclosporine and mycophenolate in an orthotopic porcine-to-rat corneal xenotransplantation. J. Korean Med. Sci., 2008-06-01;23(3):492-501. 2008-06-01 [PMID: 18583888] (ELISA Development, Rat)
• Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, Wee WR, Lee JH The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells, 2008-01-10;26(4):1047-55. 2008-01-10 [PMID: 18192235] (ELISA Development, Rat)
• Roche M, Diamond M, Finn DP In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J. Neuroimmunol., 2006-09-29;181(1):57-67. 2006-09-29 [PMID: 17011047] (ELISA Development, Rat)

Bioinformatics

• Gene Symbol: IL10
• Uniprot:
  • P29456()